SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

SynAct Pharma AB ("SynAct") today announced it will host a conference call on July 7 at 13:00 CEST focused on the positive topline results from the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency.

The call will be hosted by Chairman Dr. Torbjørn Bjerke, CEO Jeppe Øvlesen and CSO Thomas Jonassen. The study’s principal investigator Dr. Mauro Teixeira will also join. The presentation will be in English and is followed by a Q&A session.

The conference call will be broadcast live on the web via the link: https://tv.streamfabriken.com/synact-pharma-2021-07-07

Telephone number for the conference call is:

SE: +46 8 5055 8359 

UK: +44 3333 009 267 

US: +1 6 467 224 957

The information was submitted, through the agency of the below contact person, for publication on July 2, 2021.

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                          Thomas Jonassen

CEO, SynAct Pharma AB                                        CSO, SynAct Pharma AB

Phone: +45 28 44 75 67                                           Phone: +45 40 15 66 69

Mail: joo@synactpharma.com                                 Mail: tj@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: www.synactpharma.com.

About AP1189

The mechanism of action of SynAct Pharma´s lead compound AP1189 is to promote resolution of inflammation through melanocortin receptor activation directly on macrophages, thereby reducing the pro-inflammatory activity of macrophages and by stimulating so-called macrophage efferocytosis, a specific ability to clear inflammatory cells (J Immun 2015, 194:3381-3388). This effect has shown to be effective in disease models of inflammatory and autoimmune diseases and the clinical potential of the approach is currently tested in a clinical phase 2 study in patients with active rheumatoid arthritis, nephrotic syndrome and Covid-19 ARDS.

https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2&rank=1.

https://clinicaltrials.gov/ct2/show/NCT04456816?term=AP1189&draw=2&rank=2.